0000000000041016

AUTHOR

Piero Ruscitti

showing 73 related works from this author

Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients

2016

Adult-onset Still’s disease (AOSD) is a systemic inflammatory condition of unknown aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a multicentric data collection to characterize the clinical phenotype of Italian patients with AOSD. Data from 245 subjects diagnosed with AOSD were collected by 15 centres between March and May 2013. The diagnosis was made following Yamaguchi’s criteria. Data regarding clinical manifestations, laboratory features, disease course and treatments were reported and compared with those presented in other published series of different et…

Male0301 basic medicinePediatricsAdult-onset Still's diseaseSettore MED/16 - REUMATOLOGIALeukocytosisClinical presentationArthritisComorbidityDiseaseLaboratory finding0302 clinical medicineAdrenal Cortex HormonesLeukocytosisAdult-onset Still’s diseaseBiologic drugsMedicine (all)General MedicineMiddle AgedRashRetrospective studyTreatment OutcomeItalyAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; Rheumatology; Medicine (all)Antirheumatic AgentsFemalemedicine.symptomStill's Disease Adult-OnsetAdultLaboratory findingsmedicine.medical_specialtyAdolescentFeverNOYoung Adult03 medical and health sciencesRheumatologyInternal medicinemedicineHumansAgedRetrospective Studies030203 arthritis & rheumatologybusiness.industryAdult-onset Still’s disease; Biologic drugs; Clinical presentation; Laboratory findings; Retrospective study; RheumatologyRetrospective cohort studymedicine.diseaseNeutrophiliaRheumatologySurgery030104 developmental biologybusinessBiologic drug
researchProduct

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing ma…

2015

In this paper, we aimed to evaluate the levels of ferritin enriched in H subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the cells expressing these 2 molecules, in the bone marrow (BM) and liver biopsies obtained from adult onset Still's disease (AOSD) patients who developed macrophage activation syndrome (MAS), and correlating these data with the severity of the disease. Twenty-one patients with MAS-associated AOSD underwent BM biopsy and among them, 9 patients with hepatomegaly and elevated liver enzymes underwent liver biopsy. All the samples were stained by both immunohistochemistry and immunofluorescence. A statistical analysis was performed to estimate the p…

Adult-OnsetAdultPathologymedicine.medical_specialtyApoferritinImmunologyAdult-onset Still's disease; Hyperferritinemia; Macrophage activation syndrome; Adult; Age of Onset; Animals; Apoferritins; Bone Marrow; Humans; Liver; Macrophage Activation Syndrome; Still's Disease Adult-Onset; Immunology; Immunology and Allergy; Medicine (all)ImmunofluorescenceAdult-onset Still's diseaseBone MarrowBiopsymedicineAnimalsHumansImmunology and AllergyAge of Onsetmedicine.diagnostic_testbiologyCD68business.industryAnimalMacrophage Activation SyndromeMedicine (all)medicine.diseaseStill's DiseaseFerritinmedicine.anatomical_structureLiverMacrophage activation syndromeLiver biopsyApoferritinsbiology.proteinImmunohistochemistryBone marrowHyperferritinemiabusinessStill's Disease Adult-OnsetHuman
researchProduct

Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification

2021

Abstract Objectives To stratify adult-onset Still’s disease (AOSD) patients in distinct clinical subsets to be differently managed, by using a multi-dimensional characterization. Methods AOSD patients were evaluated by using a hierarchical unsupervised cluster analysis comprising age, laboratory markers systemic score and outcomes. The squared Euclidean distances between each pair of patients were calculated and put into a distance matrix, which served as the input clustering algorithm. Derived clusters were descriptively analysed for any possible difference. Results Four AOSD patients clusters were identified. Disease onset in cluster 1 was characterized by fever (100%), skin rash (92%) an…

myalgiaAdultmedicine.medical_specialtyAdult-onset Still's diseaseFeverprecision medicineArthritisAdult-onset Still's diseaseGastroenterologyRheumatologyInternal medicinemedicineSore throatHumansPharmacology (medical)Adult-onset Still’s diseasebiologybusiness.industryMortality rateArthritisExanthemaMiddle Agedmedicine.diseaseRashFerritinC-Reactive ProteinAdult-onset Still’s disease; precision medicineFerritinsMulti dimensionalbiology.proteinmedicine.symptombusinessStill's Disease Adult-OnsetAlgorithmsBiomarkers
researchProduct

Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psori…

2016

Objective To investigate the expression and tissue distribution of Th9-related cytokines in patients with psoriatic arthritis (PsA). Methods Quantitative gene expression analysis of Th1, Th17, and Th9 cytokines was performed in intestinal biopsy samples obtained from patients with PsA, HLA-B27-positive patients with ankylosing spondylitis (AS), patients with Crohn's disease (CD), and healthy controls. Expression and tissue distribution of interleukin-23 (IL-23), IL-17, IL-22, IL-9, and IL-9 receptor (IL-9R) were evaluated by immunohistochemistry and confocal microscopy. Flow cytometry was used to study the frequency of Th9 cells among peripheral blood, lamina propria, and synovial fluid mon…

0301 basic medicinePathologymedicine.medical_specialtyImmunologyHigh endothelial venulesArthritisInflammationPeripheral blood mononuclear cell03 medical and health sciences0302 clinical medicineRheumatologymedicineImmunology and AllergyInterleukin 9030203 arthritis & rheumatologyLamina propriabusiness.industrymedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureImmunologyPaneth cellmedicine.symptomSynovial membranebusinessArthritis & Rheumatology
researchProduct

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

2019

AbstractSystemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells (MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from different tissues, may differently respond to the SSc microenvironment. The miRs array was used for the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated …

Adult0301 basic medicineTherapeutic gene modulationAutoimmune diseasesCellular differentiationGene regulatory networklcsh:MedicineBone Marrow CellsBiologyRegenerative medicineArticle03 medical and health sciences0302 clinical medicinemicroRNAmedicineHumansGene Regulatory Networkslcsh:ScienceCells CulturedSystemic SclerosiCell ProliferationRegulation of gene expressionScleroderma SystemicMultidisciplinarySequence Analysis RNAGene Expression ProfilingMesenchymal stem celllcsh:RCell DifferentiationMesenchymal Stem CellsSettore MED/16 - ReumatologiaMicroRNAs030104 developmental biologymedicine.anatomical_structureAdipose TissueGene Expression RegulationCancer researchSystemic sclerosisFemalelcsh:QBone marrow030217 neurology & neurosurgeryScientific Reports
researchProduct

Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Ita…

2018

Objective.Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, which can complicate adult-onset Still disease (AOSD). We investigated AOSD clinical features at the time of diagnosis, to assess predictors of MAS occurrence. Further, we analyzed the outcomes of patients with AOSD who experience MAS.Methods.Patients with AOSD admitted to any Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale center were retrospectively analyzed for features typical of AOSD, MAS occurrence, and their survival rate.Results.Of 119 patients with AOSD, 17 experienced MAS (12 at admission and 5 during followup). Twelve patients with MAS at first admission diff…

AdultMalemusculoskeletal diseases0301 basic medicineAdult onset still diseasemedicine.medical_specialtyAbdominal painMultivariate analysisSurvivalImmunologyStill DiseaseComorbidityGastroenterology03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinePrevalencemedicineHumansImmunology and AllergySurvival rateRetrospective Studies030203 arthritis & rheumatologyFerritinHemophagocytic lymphohistiocytosisbiologybusiness.industryIncidencefungiMiddle AgedHyperferritinemic syndromemedicine.diseaseSurvival RateFerritin030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeFerritinsCohortbiology.proteinAdult onset still disease; Ferritin; Hyperferritinemic syndrome; Macrophage activation syndrome; Survival; Rheumatology; Immunology and Allergy; ImmunologyFemalemedicine.symptombusinessStill's Disease Adult-OnsetThe Journal of Rheumatology
researchProduct

H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi…

2016

Summary Adult-onset Still's disease (AOSD) patients may show an evanescent salmon-pink erythema appearing during febrile attacks and reducing without fever. Some patients may experience this eruption for many weeks. During AOSD, exceptionally high serum levels of ferritin may be observed; it is an iron storage protein composed of 24 subunits, heavy (H) subunits and light (L) subunits. The ferritin enriched in L subunits (L-ferritin) and the ferritin enriched in H subunits (H-ferritin) may be observed in different tissues. In this work, we aimed to investigate the skin expression of both H-and L-ferritin and the number of macrophages expressing these molecules from AOSD patients with persist…

Male0301 basic medicinePathologymedicine.medical_specialtyAdult-onset Still's diseaseDermal immune systemErythemaMacrophageBiopsyImmunologyAntigens Differentiation MyelomonocyticGene ExpressionDiseaseAdult-onset Still's diseaseMonocytesH-Ferritin03 medical and health sciences0302 clinical medicineAntigens CDadult-onset Still's disease; dermal immune system; ferritin; hyperferritinaemic syndrome; macrophagemedicineHumansImmunology and AllergyMonocytes macrophagesMacrophageRNA MessengerSkin030203 arthritis & rheumatologyFerritinbiologyCD68MacrophagesOriginal ArticlesFerritinSettore MED/16 - Reumatologia030104 developmental biologyApoferritinsImmunologyLeukocytes Mononuclearbiology.proteinCytokinesFemaleInflammation Mediatorsmedicine.symptomHyperferritinaemic syndromeStill's Disease Adult-OnsetBiomarkersClinical and Experimental Immunology
researchProduct

Development and implementation of the AIDA international registry for patients with Still's disease

2022

ObjectiveAim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder.MethodsThis Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients' management. The co…

RegistrySettore MED/16 - REUMATOLOGIAresearchtreatmentprecision medicinerare diseasesGeneral Medicinepersonalized medicineautoinflammatory diseasesSettore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseases personalized medicine precision medicine rare diseases research treatmentStill's diseaseautoinflammatory diseases; personalized medicine; precision medicine; rare diseases; research; treatmentHuman medicine
researchProduct

Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and De…

2016

Objective.Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule.Methods.After ethical approval, mesenchymal stem cells (MSC) and fibroblasts …

0301 basic medicineAdultMalePathologymedicine.medical_specialtyImmunologyADAM12 Protein03 medical and health sciencesYoung AdultRheumatologyFibrosisTransforming Growth Factor betamedicineImmunology and AllergyHumansProgenitor cellMyofibroblastsSkinintegumentary systembusiness.industryMedicine (all)FIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Rheumatology; Immunology; Immunology and AllergyMesenchymal stem cellTransdifferentiationMesenchymal Stem CellsMiddle Agedmedicine.diseaseFibrosisActinsUp-RegulationSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structurePERICYTEFIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)SYSTEMIC SCLEROSISCell TransdifferentiationScleroderma DiffuseFemalePericyteBone marrowbusinessPericytesMyofibroblastTransforming growth factorThe Journal of rheumatology
researchProduct

Adult-onset Still's disease with elderly onset: results from a multicentre study

2021

Objective In this study, we aimed to describe the clinical characteristics, life-threatening complications occurrence, and mortality of adult-onset Still's disease (AOSD) patients with elderly onset. Methods A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was performed. Results Out of 221 assessed patients, 37 (16.7%) had an onset of the disease aged over 60 years. When compared with younger patients, these were characterised by a higher prevalence of pericarditis (p=0.008), comorbidities (p < 0.0001), and mortality (p=0.023). Age predicted the presence of serositis …

Lung DiseasesAdult-OnsetAdultcomorbiditieImmunologyadult-onset Still's diseasecomorbiditiesLung Diseaseserositisadult-onset Still's disease; aging; serositis; parenchymal lung disease; comorbidities; Adult; Aged; Humans; Middle Aged; Retrospective Studies; Lung Diseases; Macrophage Activation Syndrome; Serositis; Still's Disease Adult-OnsetRheumatologyRetrospective StudieImmunology and AllergyHumansRetrospective StudiesAgedcomorbidities.SerositiMacrophage Activation SyndromeagingMiddle AgedStill's Diseaseadult-onset Still's disease; aging; serositis; parenchymal lung disease; comorbiditiesStill's Disease Adult-Onsetparenchymal lung diseaseHuman
researchProduct

Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome

2022

ObjectiveThe aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) international Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination.MethodsThis Registry is a clinical, physician-driven, population- and electronic-based instrument designed for the retrospective and prospective collection of real-life data. Data gathering is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain real-world evidence for daily patients' management. The Registry may potentially communicate with other on-line tools dedicated to VEXAS syndrome, thu…

RegistryKeywords: autoinflammatory diseases; clinical management; precision medicine; rare diseases; research; treatment.Settore MED/16 - REUMATOLOGIAresearchtreatmentprecision medicinerare diseasesrare diseaseGeneral Medicineautoinflammatory diseasestreatment.Settore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseaseVEXAS syndromeclinical managementHuman medicineKeywords: autoinflammatory diseases
researchProduct

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Ita…

2019

Background Rheumatoid arthritis (RA) is associated with an increased risk of morbidity and mortality, when compared with general population, largely due to enhanced atherosclerotic disease. In this work, we aimed at assessing both occurrence and predictive factors of subclinical and clinical atherosclerosis in RA. Methods From January 1, 2015, to December 31, 2015, consecutive participants with RA, admitted to Italian Rheumatology Units, were assessed in the GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. After that, those participants were followed up in a 3-year, prospective, observational study, assessing the occurrence of subclinical and clinical ather…

0301 basic medicineMaleTime Factorslcsh:Diseases of the musculoskeletal systemType 2 diabetesComorbidityArthritis Rheumatoid0302 clinical medicineProspective StudiesSubclinical infectionAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceAge FactorsType 2 diabetesMiddle AgedPrognosisCardiovascular diseaseSurvival RateCardiovascular diseasesItalyRheumatoid arthritisAtherosclerosiCohortDisease ProgressionFemaleResearch ArticleAdultmedicine.medical_specialtyRemissionPopulation03 medical and health sciencesYoung AdultAge DistributionSex FactorsInternal medicinemedicineHumansSex DistributionRheumatoid arthritiseducationRheumatoid arthritiAged030203 arthritis & rheumatologybusiness.industryAtherosclerosis; Cardiovascular diseases; Remission; Rheumatoid arthritis; Type 2 diabetesmedicine.diseaseAtherosclerosisRheumatologySettore MED/16 - Reumatologia030104 developmental biologyBlood pressurelcsh:RC925-935businessFollow-Up Studies
researchProduct

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

2019

Abstract Background Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma. Methods Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasm…

Adultmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHyaluronic acidMicrocheiliaGastroenterologySystemic sclerosi030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyPlatelet-rich plasmaFibrosisInternal medicineHyaluronic acidmedicineHumansProspective StudiesHyaluronic acid; Platelet-rich plasma; Systemic sclerosis; TherapySkin030203 arthritis & rheumatologyScleroderma SystemicViscosupplementsMicrostomiabusiness.industryMiddle Agedmedicine.diseaseConnective tissue diseaseElasticityLipRheumatologySettore MED/16 - ReumatologiaTreatment OutcomechemistryPlatelet-rich plasmaQuality of LifeSystemic sclerosisFemaleTherapylcsh:RC925-935businessResearch ArticleArthritis Research & Therapy
researchProduct

Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleot…

2015

Summary A better understanding about the mechanisms involved in the pathogenesis of type 2 diabetes mellitus (T2D) showed that inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin (IL)-1β play a pivotal role, mirroring data largely reported in rheumatoid arthritis (RA). IL-1β is produced mainly by monocytes (MO), and hyperglycaemia may be able to modulate, in the cytoplasm of these cells, the assembly of a nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3)-inflammosome, a cytosolic multi-protein platform where the inactive pro-IL-1β is cleaved into active form, via caspase-1 activity. In this paper, we evaluated the production of IL-1 β …

Maletype 2 diabetes mellituInflammasomesMessengerIL-1β; NLRP3-inflammasome; rheumatoid arthritis; type 2 diabetes mellitus; Adult; Arthritis Rheumatoid; Carrier Proteins; Caspase 1; Cells Cultured; Diabetes Mellitus Type 2; Enzyme Activation; Female; Glucose; Humans; Hyperglycemia; Inflammasomes; Inflammation; Interleukin-1beta; Leukocytes Mononuclear; Male; Middle Aged; RNA Messenger; Tumor Necrosis Factor-alphaInterleukin-1betaArthritisPyrin domainInflammasomeArthritis RheumatoidRheumatoidImmunology and AllergyCells CulturedCulturedCaspase 1InterleukinDiabetes MellituMiddle AgedIL-1βTumor necrosis factor alphaNLRP3-inflammasomeFemalemedicine.symptomType 2ArthritiHumanAdultmedicine.medical_specialtyMononuclearImmunologyCaspase 1InflammationProinflammatory cytokineInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansRNA MessengerInflammationbusiness.industryTumor Necrosis Factor-alphaType 2 Diabetes MellitusOriginal Articlesrheumatoid arthritiLeukocytemedicine.diseaseEnzyme ActivationEndocrinologyGlucoseDiabetes Mellitus Type 2HyperglycemiaImmunologyLeukocytes MononuclearRNACellbusinessCarrier ProteinsCarrier Protein
researchProduct

Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of…

2020

ObjectiveTo assess the predictive role of ferritin and C-reactive protein (CRP) on occurrence of macrophage activation syndrome (MAS) and mortality in patients with adult onset Still's disease (AOSD), a rare and severe disease, included in the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort.MethodsThe predictive role, at the time of diagnosis, of serum levels of ferritin and CRP on occurrence of MAS and mortality, was evaluated by logistic regression analyses and receiver-operating characteristic (ROC) curves were built to identify patients at high risk of MAS and mortality, respectively.ResultsIn assessed 147 patients with AOSD, levels of ferri…

0301 basic medicinemyalgiaAdult-OnsetMalePredictive Value of TestPathology and Laboratory MedicineLogistic regressionBiochemistryGastroenterologyCohort StudiesMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesMultidisciplinarybiologyMacrophage Activation SyndromeStatisticsQRMiddle AgedC-Reactive ProteinsC-Reactive ProteinPredictive value of testsPhysical SciencesCohortRegression AnalysisMedicineFemalemedicine.symptomStill's Disease Adult-OnsetResearch ArticleCohort studyHumanAdultmedicine.medical_specialtyPatientsLogistic ModelInflammatory DiseasesSciencePainStill's Disease Adult-Onset.Research and Analysis Methods03 medical and health sciencesAdult; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Ferritins; Humans; Logistic Models; Macrophage Activation Syndrome; Male; Middle Aged; Predictive Value of Tests; ROC Curve; Still's Disease Adult-OnsetSigns and SymptomsDiagnostic MedicinePredictive Value of TestsInternal medicinemedicineHumansStatistical Methods030203 arthritis & rheumatologyFerritinbusiness.industryC-reactive proteinBiology and Life SciencesProteinsProtein ComplexesMyalgiaBiomarkermedicine.diseaseStill's DiseaseHealth CareFerritin030104 developmental biologyLogistic ModelsROC CurveMacrophage activation syndromeMultivariate AnalysisFerritinsbiology.proteinCohort StudiebusinessMathematicsBiomarkers
researchProduct

SAT0025 MIR 106A, MIR 19A-B, MIR 20A and MIR21A regulate vγ9vδ2 functions participating in the inflammatory responses occurring in rheumatoid arthrit…

2017

Background miRNAs are non-coding RNAs which have significant roles in regulating gene expression. The miR17-92 cluster appears to be a key factor in the inflammatory pathways activated during RA. Objectives In this study we aimed to evaluate miR17–92 expression and functions in γδ T cell subsets in RA patients, γδ T cells, in fact produce proinflammatory cytokines such as IFN-g, IL-6 and IL-8 that may contribute to the inflammatory responses in RA. Methods Heparinized peripheral blood from 10 early RA untreated patients and 10 healthy donors was obtained for this study. Polyclonal Vγ9Vδ2 T cell lines were generated first by magnetic isolation followed by sorting (FACSAria) and further analy…

medicine.diagnostic_testbusiness.industryEffectormedicine.medical_treatmentT cellProinflammatory cytokineFlow cytometryCytokinemedicine.anatomical_structureDownregulation and upregulationmicroRNAGene expressionCancer researchMedicinebusinessPoster Presentations
researchProduct

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life exp…

2022

ObjectiveInterleukin (IL)-1 inhibitors are largely employed in patients with Still’s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the IL-1β antagonist canakinumab prescribed as first-line biologic agent between the systemic and the chronic-articular Still’s disease.MethodsData were drawn from the retrospective phase of the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to Still’s disease. Patients with Still’s disease classified according to internationally accepted criteria (Yamaguchi criteria and/or Fa…

AOSD; adult onset Still’s disease; autoinflammatory diseases; biological therapy; interleukin-1; sJIA; systemic juvenile idiopathic arthritisadult onset Still’s diseaseAOSD adult onset Still’s disease autoinflammatory diseases biological therapy interleukin-1 sJIA systemic juvenile idiopathic arthritisSettore MED/38 - Pediatria Generale E Specialisticasystemic juvenile idiopathic arthritisbiological therapyAOSDGeneral Medicineautoinflammatory diseasesinterleukin-1sJIAFrontiers in Medicine
researchProduct

Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo I…

2020

Abstract Background Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the disease comparing patients with LD and those without. Methods A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and pre…

Lung DiseasesmyalgiaAbdominal painmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemDiseaseSeverity of Illness IndexYoung AdultAdult onset Still's diseaseInternal medicineCase fatality ratemedicineHumansMortalityYoung adultSurvival rateAgedRetrospective StudiesAdult onset Still’s diseasebusiness.industryMortality rateAdult onset Still's disease; Lung disease; MortalityLung diseaseCohortMortality.lcsh:RC925-935medicine.symptombusinessStill's Disease Adult-OnsetBiomarkersResearch ArticleArthritis Research & Therapy
researchProduct

Downregulation of miRNA17-92 cluster marks Vγ9Vδ2 T cells from patients with rheumatoid arthritis

2018

Abstract Background We aimed to evaluate the phenotype, function, and microRNA (miRNA)17–92 cluster expression in Vγ9Vδ2 T-cell subsets and the correlation with immune response in rheumatoid arthritis (RA) patients. Methods Peripheral blood from 10 early RA untreated patients and 10 healthy donors (HD) was obtained. Polyclonal Vγ9Vδ2 T-cell lines were generated and analysed by flow cytometry. Analysis of miRNA17–92 cluster expression was performed by real-time polymerase chain reaction (RT-PCR), and expression of mRNA target genes was also studied. Results A remarkable change in the distribution of Vγ9Vδ2 T-cell functional subsets was observed in the peripheral blood of RA patients compared…

AdultMale0301 basic medicinemiRNA17–92lcsh:Diseases of the musculoskeletal systemInflammatory cytokineImmunologyDown-RegulationBiologyγδ T cellsProinflammatory cytokineFlow cytometryArthritis RheumatoidPathogenesis03 medical and health sciences0302 clinical medicineImmune systemRheumatologyT-Lymphocyte SubsetsInflammatory cytokines; miRNA17-92; Rheumatoid arthritis; γδ T cells; Rheumatology; Immunology and Allergy; ImmunologymicroRNAmedicineHumansImmunology and AllergyRheumatoid arthritisRheumatoid arthritiγδ T cellmedicine.diagnostic_testEffectorInterleukinMiddle AgedInflammatory cytokinesPhenotypemiRNA17-92MicroRNAsSettore MED/16 - Reumatologia030104 developmental biology030220 oncology & carcinogenesisImmunologyFemalelcsh:RC925-935Research Article
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct

H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome

2017

Summary Macrophage activation syndrome (MAS) is hyperinflammatory life-threatening syndrome, associated typically with high levels of serum ferritin. This is an iron storage protein including heavy (H) and light (L) subunits, categorized on their molecular weight. The H-/L subunits ratio may be different in tissues, depending on the specific tissue and pathophysiological status. In this study, we analysed the bone marrow (BM) biopsies of adult MAS patients to assess the presence of: (i) H-ferritin and L-ferritin; (ii) CD68+/H-ferritin+ and CD68+/L-ferritin+; and (iii) interleukin (IL)-1β, tumour necrosis factor (TNF) and interferon (IFN)-γ. We also explored possible correlations of these re…

0301 basic medicineBiopsymedicine.medical_treatment0302 clinical medicineBone MarrowcytokineImmunology and AllergyInterleukinBlood ProteinsSyndromeMiddle AgedC-Reactive ProteinCytokinemedicine.anatomical_structureCytokinesTumor necrosis factor alphaInflammation Mediatorsmedicine.symptommacrophage activation syndromeAdultImmunologyAntigens Differentiation MyelomonocyticInflammationmacrophageBiologyProinflammatory cytokine03 medical and health sciencesAntigens CDmedicineHumansAgedRetrospective StudiesInflammation030203 arthritis & rheumatologyMacrophagesferritinOriginal ArticlesMacrophage Activationmedicine.diseaseFerritinSettore MED/16 - Reumatologia030104 developmental biologyMacrophage activation syndromeApoferritinsImmunologybiology.proteinBone marrowCytokine; Ferritin; Hyperferritinaemic syndrome; Macrophage; Macrophage activation syndrome; Immunology and Allergy; Immunologycytokine; ferritin; hyperferritinaemic syndrome; macrophage; macrophage activation syndromehyperferritinaemic syndrome
researchProduct

Erratum to “Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren’s syndrome? Association between clinical, histopathologica…

2015

Pathologymedicine.medical_specialtyAnesthesiology and Pain MedicineS syndromeRheumatologybusiness.industryMedicineArthritisRetrospective cohort studySalivary gland biopsybusinessmedicine.diseaseRheumSeminars in Arthritis and Rheumatism
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies

2015

In recent years, mesenchymal stromal cells (MSCs) have been largely investigated and tested as a new therapeutic tool for several clinical applications, including the treatment of different rheumatic diseases. MSCs are responsible for the normal turnover and maintenance of adult mesenchymal tissues as the result of their multipotent differentiation abilities and their secretion of a variety of cytokines and growth factors. Although initially derived from bone marrow, MSCs are present in many different tissues such as many peri-articular tissues. MSCs may exert immune-modulatory properties, modulating different immune cells in both in vitro and in vivo models, and they are considered immune-…

AdultCancer ResearchpathogenesiCellular differentiationImmunologyCell- and Tissue-Based TherapyBone Marrow CellsMesenchymal Stem Cell TransplantationRegenerative MedicineRegenerative medicineAutoimmune DiseaseAutoimmune DiseasesChondrocytesImmune systemIn vivoBone MarrowRheumatic DiseasesmedicineHumansImmunology and Allergyrheumatic diseaseGenetics (clinical)TransplantationOsteoblastsMesenchymal Stromal Cellbusiness.industryOsteoblastMesenchymal stem cellMesenchymal Stem CellsCell DifferentiationCell BiologyChondrocyteClinical trialmedicine.anatomical_structureregenerative therapyOncologymesenchymal stromal cells; pathogenesis; regenerative therapy; rheumatic disease; Adult; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Chondrocytes; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Osteoblasts; Regenerative Medicine; Rheumatic DiseasesImmunologyBone Marrow CellBone marrowStem cellbusinessHuman
researchProduct

THU0164 Subclinical atherosclerosis and cardiovascular events in italian patients with rheumatoid arthritis: results from multicenter girrcs (gruppo …

2017

Background Several studies showed a close relationship between Rheumatoid Arthritis (RA) and accelerated atherosclerosis [1,2]. At the best of our knowledge, no such study has been carried out in a large Italian series. Objectives To investigate the prevalence of presence of subclinical atherosclerosis and history of cardio-cerebrovascular events (CVEs), in 1266 patients consecutively admitted to Rheumatology Units throughout the whole Italy. Methods From 01/01/2015 to 31/12/2015, 1266 consecutive patients admitted to GIRRCS centres, satisfying ACR/EULAR criteria for RA were investigated for: i. traditional cardiovascular risk factors: gender, age, smoking habit, cholesterol, triglycerides,…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtybusiness.industryType 2 diabetesmedicine.diseaseRheumatologySurgery03 medical and health sciences030104 developmental biology0302 clinical medicineRheumatoid arthritisInternal medicineHeart failuremedicineMyocardial infarctionMetabolic syndromebusinessStrokeSubclinical infection
researchProduct

Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multi…

2017

Supplemental Digital Content is available in the text

Blood GlucoseMalerheumatoid arthritisCross-sectional studyType 2 diabetesTriglycerideArthritis Rheumatoid0302 clinical medicineRisk FactorsCardiovascular DiseasePrevalence030212 general & internal medicineMyocardial infarctionStrokeSubclinical infectionAged 80 and overMetabolic SyndromeMetabolic Syndrome XGeneral MedicineMiddle Agedinflammatory processCholesterolItalyCardiovascular DiseasesRheumatoid arthritisAtherosclerosiHypertensionComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleHumanResearch ArticleAdultmedicine.medical_specialtyAdolescentsubclinical atherosclerosisObservational Study03 medical and health sciencesYoung Adultcardiovascular eventsInternal medicinemedicineHumansTriglyceridesAged030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industryRisk Factor6900medicine.diseaseAtherosclerosisCross-Sectional StudiesDiabetes Mellitus Type 2Physical therapyMetabolic syndromebusinessRheumatismtraditional cardiovascular risk factorMedicine
researchProduct

Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

2017

Summary T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the pathogenesis of several autoimmune diseases. The exact role of IL-9 and Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β expression were assessed in skin and kidney biopsies of SSc patients and healthy controls (HC) by immunohistochemistry (IHC). The cellular source of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-producing cells were also studied by flow cytometry. The functional relevance of IL-9 increased expression in SSc …

AdultCD4-Positive T-LymphocytesMale0301 basic medicineIL-9 ILC2 systemic sclerosis Th9Thymic stromal lymphopoietinNeutrophilsImmunologyExtracellular TrapsPeripheral blood mononuclear cellFlow cytometryILC2Pathogenesis03 medical and health sciencesThymic Stromal LymphopoietinTransforming Growth Factor betaProto-Oncogene ProteinsmedicineHumansImmunology and AllergyTh9Interleukin 9Mast CellsAutoantibodiesSkinReceptors Interleukin-9B-LymphocytesScleroderma Systemicmedicine.diagnostic_testintegumentary systembusiness.industryInterleukin-9InterleukinCell DifferentiationOriginal ArticlesNeutrophil extracellular trapsMiddle AgedIL-9Settore MED/16 - Reumatologia030104 developmental biologyImmunologyTrans-ActivatorsCytokinesImmunohistochemistryFemaleInterleukin-4businesssystemic sclerosi
researchProduct

Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome.

2022

ObjectiveThe present paper describes the design, development, and implementation of the AutoInflammatory Disease Alliance (AIDA) International Registry specifically dedicated to patients with Schnitzler's syndrome.MethodsThis is a clinical physician-driven, population- and electronic-based registry implemented for the retrospective and prospective collection of real-life data from patients with Schnitzler's syndrome; the registry is based on the Research Electronic Data Capture (REDCap) tool, which is designed to collect standardized information for clinical research, and has been realized to change over time according to future scientific acquisitions and potentially communicate with other…

RegistrySettore MED/38 - Pediatria Generale E SpecialisticaSchnitzler syndromeSettore MED/16 - REUMATOLOGIAautoinflammatory diseasebiotherapiesbiotherapierare diseaseGeneral Medicineautoinflammatory disease; biotherapies; interleukin-1; international registry; personalized medicine; rare diseasepersonalized medicineinternational registryinterleukin-1Frontiers in medicine
researchProduct

The AutoInflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases

2022

ObjectiveThe present manuscript aims to describe an international, electronic-based, user-friendly and interoperable patient registry for monogenic autoinflammatory diseases (mAIDs), developed in the contest of the Autoinflammatory Diseases Alliance (AIDA) Network.MethodsThis is an electronic platform, based on the Research Electronic Data Capture (REDCap) tool, used for real-world data collection of demographics, clinical, laboratory, instrumental and socioeconomic data of mAIDs patients. The instrument has flexibility, may change over time based on new scientific acquisitions, and communicate potentially with other similar registries; security, data quality and data governance are corner …

RegistrySettore MED/38 - Pediatria Generale E SpecialisticaSettore MED/16 - REUMATOLOGIAautoinflammatory diseaseprecision medicineAutoinflammatory diseasesrare diseasesHuman medicinepersonalized medicineGeneral Medicinerare diseases.autoinflammatory diseases; international registry; personalized medicine; precision medicine; rare diseasesinternational registry
researchProduct

OP0090 THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVA…

2019

Background The systemic inflammatory process and the “traditional” cardiovascular (CV) risk factors could synergize the enhancement of CV burden in rheumatoid arthritis (RA) [1]. Objectives To assess the occurrence and the predictive factors of subclinical and clinical atherosclerosis in patients with RA. Methods During 2015, consecutive patients, admitted to Italian Rheumatology Units, were assessed in GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort [2]. After that, patients were followed-up in a 3-year, prospective, observational study, assessing the occurrence of subclinical (carotid and/or peripheral arteries atherosclerotic lesions detected by ultrasou…

medicine.medical_specialtyLow dosagebusiness.industryviruseseducationmedicine.diseaseInternal medicineSubclinical atherosclerosisRheumatoid arthritisCohortUltrasound imagingmedicineObservational studyIn patientbusinessSubclinical infectionOral Presentations
researchProduct

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

2017

Abstract Although the better management of rheumatoid arthritis (RA) has significantly improved the long-term outcome of affected patients, a significant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conflicting results are still av…

Blood GlucoseMalerheumatoid arthritisTime FactorsCross-sectional studyType 2 diabetesAdrenal Cortex HormoneBody Mass IndexArthritis Rheumatoid0302 clinical medicineimpaired fasting glucoseAdrenal Cortex HormonesRisk FactorsRheumatoidCardiovascular DiseasePrevalence030212 general & internal medicineMedicine (all)Diabetes MellituGeneral MedicineMiddle AgedC-Reactive ProteinCholesterolcardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes;Cardiovascular DiseasesCohortHypertensionFemaletype 2 diabetesCase-Control Studiecardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes; Adrenal Cortex Hormones; Adult; Aged; Arthritis Rheumatoid; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Middle Aged; Prevalence; Risk Factors; Time Factors; Medicine (all)Type 2Research ArticleArthritiHumanAdultcardiovascular riskmedicine.medical_specialtyTime FactorObservational StudyNO03 medical and health sciencesInternal medicineDiabetes mellitusGlucose Intolerancemedicinecardiovascular risk impaired fasting glucose inflammation rheumatoid arthritis type 2 diabetesHumansAged030203 arthritis & rheumatologyCross-Sectional Studietype 2 diabetebusiness.industryRisk Factor6900Case-control studyrheumatoid arthritimedicine.diseaseImpaired fasting glucoseSettore MED/16 - ReumatologiaCross-Sectional StudiesDiabetes Mellitus Type 2inflammationCase-Control StudiesMetabolic syndromebusinessBody mass index
researchProduct

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

2020

Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in …

Male0301 basic medicineEye DiseasesTRAPSColchicineAIDA NetworkGene mutationGastroenterologyReceptors Tumor Necrosis Factorchemistry.chemical_compoundSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineReceptorsPathologyRB1-214ColchicineAge of OnsetYoung adultChildAmyloidosisAmyloidosisSyndromeMiddle AgedColchicine tumor necrosis factor TRAPSInflamacióPenetrancePhenotypeChild PreschoolFemaleJoint DiseasesResearch ArticleAdultRiskmedicine.medical_specialtyAdolescentFeverArticle SubjectImmunologyAdolescent; Adult; Age of Onset; Amyloidosis; Child; Child Preschool; Colchicine; Exanthema; Eye Diseases; Female; Fever; Humans; Joint Diseases; Male; Middle Aged; Mutation; Myalgia; Phenotype; Receptors Tumor Necrosis Factor; Retrospective Studies; Risk; Syndrome; Young AdultLower riskYoung Adult03 medical and health sciencesInternal medicinemedicineHumansPreschoolRetrospective StudiesInflammation030203 arthritis & rheumatologybusiness.industryTRAPSRetrospective cohort studyMyalgiaCell BiologyExanthemamedicine.disease030104 developmental biologychemistryMutationAge of onsetColchicineTumor Necrosis FactorbusinessMediators of Inflammation
researchProduct

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A S…

2020

This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p<0.05…

0301 basic medicinemyalgiaMaleAbdominal painSettore MED/16 - REUMATOLOGIATNFRSF1AGene mutationGastroenterology0302 clinical medicinePathologyMedicineRB1-214PericarditisChildPrognosisPenetranceInflamacióFamilial Mediterranean FeverAIDA networkEstudi de casosReceptors Tumor Necrosis Factor Type IChild PreschoolAutoinflammationFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdolescentGenotypetumor necrosis factorImmunologyContext (language use)Asymptomatic03 medical and health sciencesYoung AdultInternal medicineAnimalsHumansRetrospective Studies030203 arthritis & rheumatologyInflammationbusiness.industrytumor necrosis factor TRAPS AIDA networkTumor Necrosis Factor-alphaInfantTRAPSCell BiologyMyalgiaBiological productmedicine.disease030104 developmental biologyMutationCase studiesbusinessKidney diseaseMediators of Inflammation
researchProduct

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

2020

Abstract Background Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with a progressive elevation in pulmonary vascular resistance and subsequent right heart failure and death. Due to unspecific symptoms, the diagnosis of PAH is often delayed. On this basis, it is of great value to improve current diagnostic methods and develop new strategies for evaluating patients with suspected PAH. Interleukin-32 (IL-32) is a proinflammatory cytokine expressed in damaged vascular cells, and the present study aimed to assess if this cytokine could be a new biomarker of PAH during SSc. Methods The IL-32 expression was evaluated in the sera and skin sam…

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHypertension Pulmonarymedicine.medical_treatment030204 cardiovascular system & hematologyPulmonary arterial hypertensionGastroenterologyProinflammatory cytokineSystemic sclerosi03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterysystemic sclerosis; pulmonary arterial hypertension; IL-32medicineHumansskin and connective tissue diseases030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterleukinsRheumatologyInterleukin 32Cytokinemedicine.anatomical_structureIL-32; Pulmonary arterial hypertension; Systemic sclerosisIL-32Pulmonary arteryVascular resistanceSystemic sclerosisBiomarker (medicine)Immunohistochemistrylcsh:RC925-935businessBiomarkersResearch ArticleArthritis Research & Therapy
researchProduct

Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

2016

Background: Adult-onset Still's disease (AOSD) is rare inflammatory disease of unknown etiology that usually affects young adults. The more common clinical manifestations are spiking fevers, arthritis, evanescent rash, elevated liver enzymes, lymphadenopathy, hepatosplenomegaly, and serositis. The multi-visceral involvement of the disease and the different complications, such as macrophage activation syndrome, may strongly decrease the life expectancy of AOSD patients. Methods: This study aimed to identify the positive and negative features correlated with the outcome of patients. A retrospective analysis of AOSD patients prospectively admitted to three rheumatologic centers was performed t…

AdultMale0301 basic medicinemedicine.medical_specialtyPrognosiHepatosplenomegalyArthritisDiseaseAdult-onset Still's diseaseYoung Adult03 medical and health sciencesSystemic score0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansYoung adultRetrospective StudiesAdult-onset Still’s diseaseMedicine(all)030203 arthritis & rheumatologyPrognostic factorbusiness.industryMedicine (all)BiomarkerGeneral MedicineMiddle AgedPrognosismedicine.diseaseRashSurgerySettore MED/16 - Reumatologia030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeEtiologyAdult-onset Still’s disease; Macrophage activation syndrome; Prognostic factor; Systemic scoreFemalemedicine.symptombusinessStill's Disease Adult-OnsetSerositisBiomarkersHumanResearch ArticleBMC Medicine
researchProduct

FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome

2017

Background During macrophage activation syndrome (MAS), an inflammatory life-threatening syndrome, extremely high levels of serum ferritin may be observed [1]. Ferritin is an intracellular iron storage protein comprising 24 subunits that may be divided in heavy (H) subunits and light (L) subunits, based on their molecular weight [2]. The H-/L-subunits ratio may change, depending on the specific tissue and the physiologic status of the cell. In the normal condition, ferritin enriched in L subunits (L-ferritin) has been found in the liver and in the spleen, whereas the ferritin enriched in H subunits (H-ferritin), may be mainly observed in the heart and kidneys [2]. Objectives We investigated…

medicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industryCD68Spleen030204 cardiovascular system & hematologyProinflammatory cytokineFerritin03 medical and health sciences0302 clinical medicineEndocrinologymedicine.anatomical_structureWestern blotInternal medicineImmunologymedicinebiology.proteinMacrophageTumor necrosis factor alpha030212 general & internal medicineBone marrowbusinessPoster Presentations
researchProduct

Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, mu…

2021

Objectives: In rheumatoid arthritis (RA), "traditional" cardiovascular (CV) risk factors continue to be underdiagnosed and undertreated, thus increasing the risk of developing atherosclerosis. In this work, we evaluated the occurrence and predictive factors of "traditional" cardiovascular risk factors, with a focus on high blood pressure (HBP), type 2 diabetes (T2D), and metabolic syndrome (MetS), in participants with RA, in a 3-year, multicentre, prospective, observational study. Methods: To assess the occurrence and predictive factors of HBP, T2D, and MetS, consecutive participants with RA, admitted to Italian Rheumatology Units, were evaluated in the GIRRCS (Gruppo Italiano di Ricerca in…

Metabolic SyndromeArthritisImmunologyArthritis RheumatoidDiabetes Mellitus Type 2RheumatologyRisk FactorsRheumatoidHypertensionDiabetes MellitusImmunology and AllergyHumansProspective StudiesHumans; Prospective Studies; Risk Factors; Arthritis Rheumatoid; Diabetes Mellitus Type 2; Hypertension; Metabolic SyndromeType 2
researchProduct

Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome

2018

Objective To investigate the role of the interleukin-25 (IL-25)/IL-17 receptor B (IL-17RB) axis in experimental Sjogren's syndrome (SS) and in patients with primary SS and primary SS-associated lymphoma. Methods Expression of IL-25, IL-17RB, IL-17B, and tumor necrosis factor receptor-associated factor 6 (TRAF6) was analyzed on minor salivary gland (SG) samples from patients with primary SS and on parotid gland samples from patients with primary SS-associated B cell non-Hodgkin's lymphoma (NHL). IL-17RB expression and the frequencies of natural group 2 innate lymphoid cells (ILC2s), inflammatory ILC2s, and M2-polarized macrophages were assessed by flow cytometry in SG mononuclear cells and p…

0301 basic medicineMaleLymphomaMacrophageImmunologyPeripheral blood mononuclear cellSalivary GlandSalivary GlandsFlow cytometry03 medical and health sciencesMice0302 clinical medicineRheumatologyInterleukin 25AnimalsHumansMedicineImmunology and AllergyLymphocytesB cellAgedReceptors Interleukin-17medicine.diagnostic_testbusiness.industryAnimalMacrophagesInnate lymphoid cellInterleukin-17Middle Agedmedicine.diseaseImmunity InnateLymphomaSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structureSjogren's SyndromeImmunologyImmunology and Allergy; Rheumatology; ImmunologyLeukocytes MononuclearRituximabTumor necrosis factor alphaFemaleLymphocytebusiness030215 immunologymedicine.drugHuman
researchProduct

Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS

2013

Bariatric surgery represents a common approach for the control of severe morbid obesity, reducing caloric intake by modifying the anatomy of the gastrointestinal tract. Following jejunoileal bypass, a large spectrum of complications has been described, with rheumatic manifestation present in up to 20% of cases. Although bowel bypass syndrome, also called blind loop syndrome, is a well-recognized complication of jejunoileal bypass, the same syndrome was recognized in patients who had not had intestinal bypass surgery, and the term the 'bowel-associated dermatosis-arthritis syndrome' (BADAS) was coined. The pathogenesis of BADAS is as yet poorly understood and only few data concerning this is…

Short Bowel Syndromemedicine.medical_specialtyPediatricsmedicine.medical_treatmentJejunoileal bypass immune-related conditionsImmunologyJejunoileal bypassSkin DiseasesGastroenterologyImmune systemBlind loop syndromeJejunoileal BypassInternal medicinemedicineHumansImmunology and AllergyIn patientIntestinal bypassbusiness.industryBowel-associated dermatosis–arthritis syndromeArthritismedicine.diseaseCaloric intakeimmune-related conditionsBlind Loop SyndromeComplicationbusinessJejunoileal bypa
researchProduct

Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with…

2015

The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in patients injected with anti-TNFα. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were consid…

0301 basic medicineMalerheumatoid arthritispsoriatic arthritimagnetic resonance imaging (MRI)anti-tumor necrosis factor α agent; intra-articular injection; magnetic resonance imaging (MRI); psoriatic arthritis; rheumatoid arthritis; treat-to-target strategy; ultrasonography; Pharmacology; Immunology; Immunology and AllergyInflammatory arthritisAnti-Inflammatory Agentsanti-tumor necrosis factor α agentInjections Intra-ArticularArthritis Rheumatoid0302 clinical medicineAdrenal Cortex HormonesImmunology and Allergyintra-articular injectionpsoriatic arthritismedicine.diagnostic_testultrasonographyMiddle AgedArthralgiaRheumatoid arthritisJoint painAntirheumatic AgentsCorticosteroidTumor necrosis factor alphaFemalemedicine.symptomAdultmedicine.medical_specialtymedicine.drug_classImmunology03 medical and health sciencesPsoriatic arthritisInternal medicineMonoarthritismedicineHumansImmunologic FactorsAged030203 arthritis & rheumatologyPharmacologybusiness.industryTumor Necrosis Factor-alphaArthritis PsoriaticMagnetic resonance imagingOriginal Articlesrheumatoid arthritimedicine.diseaseSurgerytreat-to-target strategy030104 developmental biologybusiness
researchProduct

FRI0504 Prognostic Factors of Adult Onset Still's Disease: Analysis of 100 Cases in 3 Tertiary Referral Centers

2016

Background Adult onset Still9s disease (AOSD) is rare inflammatory disease [1]. Three different patterns of AOSD have been identified: i. monocyclic pattern, characterized by a systemic single episode; ii. polycyclic pattern, associated with multiple flares, separated by remissions; iii. chronic pattern, related to a persistently active disease with associated polyarthritis [2]. Until now, the treatment of AOSD remains largely empirical, lacking controlled clinical trials [1]. Objectives We aimed to investigate clinical data of AOSD patients and any possible correlation among these features and the outcome of patients. Methods Clinical data of 100 AOSD patients were recorded. All patients f…

medicine.medical_specialtyImmunologyArthritisGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRheumatologyInternal medicinemedicineImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyAnakinramedicine.diagnostic_testbusiness.industrymedicine.diseaseRashSurgerychemistryErythrocyte sedimentation rateMacrophage activation syndromePolyarthritismedicine.symptombusinessComplicationmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis

2021

Abstract Objective During rheumatoid arthritis (RA), the angiogenic processes, occurring with pannus-formation, may be a therapeutic target. JAK/STAT-pathway may play a role and the aim of this work was to investigate the inhibiting role of a JAK-inhibitor, tofacitinib, on the angiogenic mechanisms occurring during RA. Methods After ethical approval, JAK-1, JAK-3, STAT-1, STAT-3 and VEGF expression was evaluated on RA-synovial-tissues. In vitro, endothelial cells (ECs), stimulated with 20 ng/ml of VEGF and/or 1 μM of tofacitinib, were assessed for tube formation, migration and proliferation, by Matrigel, Boyden chamber assay and ki67 gene-expression. In vivo, 32 mice received collagen (coll…

medicine.medical_specialtyAngiogenesisArthritisDiseases of the musculoskeletal systemPharmacologyPyrroleMiceRheumatoid arthritis Angiogenesis TofacitinibPiperidinePiperidinesIn vivoInternal medicineMedicineAnimalsHumansPyrrolesRheumatoid arthritisRheumatoid arthritiTube formationMatrigelEndothelial CellTofacitinibbusiness.industryAnimalSynovial MembraneEndothelial Cellsmedicine.diseaseArthritis ExperimentalRheumatologyAngiogenesiPyrimidinesPyrimidineRC925-935TofacitinibRheumatoid arthritisAngiogenesisbusinessHumanResearch Article
researchProduct

Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Ad…

2022

ObjectiveAim of this paper is to illustrate the methodology, design, and development of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to patients with the Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome.MethodsThis is a physician-driven, non-population- and electronic-based registry proposed to gather real-world demographics, clinical, laboratory, instrumental and socioeconomic data from PFAPA patients. Data recruitment is realized through the on-line Research Electronic Data Capture (REDCap) tool. This registry is thought to collect standardized information for clinical research leading to solid real-life evidence. Th…

Registryrare disease.PFAPA syndrome; autoinflammatory diseases; international registry; personalized medicine; precision medicine; rare diseaseprecision medicinerare diseaseautoinflammatory diseases; international registry; personalized medicine; PFAPA syndrome; precision medicine; rare diseasepersonalized medicineautoinflammatory diseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory diseasePediatrics Perinatology and Child HealthHuman medicineinternational registryPFAPA syndrome
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases

2022

ObjectiveThis paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected by Undifferentiated Systemic AutoInflammatory Diseases (USAIDs).MethodsThis is an electronic registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is designed to obtain standardized information for real-life research. The instrument is endowed with flexibility, and it could change over time according to the scientific acquisitions an…

RegistrySettore MED/16 - REUMATOLOGIAprecision medicinerare diseasesGeneral Medicinepersonalized medicineautoinflammatory diseasesInternational RegistrySettore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseaseAutoinflammationHuman medicineInternational Registry; autoinflammatory diseases; personalized medicine; precision medicine; rare diseasesautoinflammatory diseases; International Registry; personalized medicine; precision medicine; rare diseases
researchProduct

Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?

2017

Introduction: Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies. Expert commentary: The difficult pathogenic scenario of MAS, in which genetic defects, predisposing diseases, and triggers are mixed together with the high mortality rat…

adult onset Still’s disease0301 basic medicineAdultAdult-onset Still's diseasemedicine.medical_treatmentImmunologyInflammationmacrophagemacromolecular substancesDisease03 medical and health sciences0302 clinical medicineRheumatic DiseasescytokinemedicineImmunology and AllergyMacrophageAnimalsHumanssystemic juvenile idiopathic arthritiMolecular Targeted TherapyChildExpert Testimony030203 arthritis & rheumatologyInflammationbusiness.industrymusculoskeletal neural and ocular physiologyMacrophage Activation Syndromehyperferritinemic syndromeMacrophage Activationmedicine.diseaseSettore MED/16 - Reumatologia030104 developmental biologyCytokinenervous systemMacrophage activation syndromeImmunologymedicine.symptombusinessExpert review of clinical immunology
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers

2016

Background Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome [1]. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokines storm the latter contributing to the development of multi-organ failure [2]. Objectives In the current study, we aimed to investigate clinical data, treatments, and outcome of adult MAS patients secondary to autoimmune rheumatic disease. Methods We retrospectively investigated clinical data, treatments, and outcome of 40 adult MAS patients secondary to autoimmune rheumatic disease…

medicine.medical_specialtyImmunologyCatastrophic antiphospholipid syndromeGastroenterologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundTocilizumabRheumatologyInternal medicinemedicineImmunology and AllergyMacrophage activation syndrome adult onset Still‟s disease hyperferritinemic syndromebusiness.industrySeptic shockProportional hazards modelMortality ratehyperferritinemic syndromeadult onset Still‟s diseasemedicine.diseaseComorbiditySurgeryMethylprednisolonechemistryMacrophage activation syndromeMacrophage activation syndromebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

2018

Objectives To review the available evidence concerning the possibility of discontinuing and/or tapering the dosage of TNF inhibitors (TNFi) in RA patients experiencing clinical remission or low disease activity. Methods A systematic review of the literature concerning the low dosage and discontinuation of TNFi in disease-controlled RA patients was performed by evaluation of reports published in indexed international journals (Medline via PubMed, EMBASE), in the time frame from 8 April 2013 to 15 January 2016. Results We analysed the literature evaluating the efficacy and the safety of two different strategies using TNFi, decreasing dosage or discontinuation, in patients experiencing clinica…

Drugmedicine.medical_specialtymedia_common.quotation_subjectMEDLINEArthritisEtanerceptDose-Response RelationshipArthritis Rheumatoid03 medical and health sciences0302 clinical medicineRheumatologyRheumatoidInternal medicinemedicineAdalimumabHumansPharmacology (medical)030212 general & internal medicinemedia_common030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisRemission Inductionmedicine.diseaseRheumatologyAntirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Humans; Remission Induction; Tumor Necrosis Factor-alpha; Rheumatology; Pharmacology (medical)DiscontinuationRheumatoid arthritisAntirheumatic AgentsDrugbusinessmedicine.drugRheumatology (Oxford, England)
researchProduct

AB0630 Cardiac Magnetic Resonance Imaging with Pharmacological Stress Perfusion in Asymptomatic Patients with Systemic Sclerosis

2016

Background Systemic Sclerosis (SSc)-heart disease (SSc-HD), although often clinically silent, significantly reduces the life-expectancy in these patients [1]. The cardiac magnetic resonance (CMR) is recognized useful tool for the diagnosis of SSc-HD and cardiac stress tests might be a helpful technique to highlight the occult myocardial involvement, which cannot be detected at rest due to compensatory mechanisms [2,3]. Objectives To evaluate the possible occult cardiac involvement in asymptomatic SSc patients by pharmacological stress, rest perfusion and delayed enhancement CMR, to identify as earlier as possible those patients at higher risk of cardiac related mortality and needing specifi…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyArthritismedicine.diseaseAsymptomaticGeneral Biochemistry Genetics and Molecular BiologyRheumatologyCoronary arteriesmedicine.anatomical_structureRheumatologyCardiac magnetic resonance imagingVentricleInternal medicineImmunology and AllergyMedicineRadiologymedicine.symptombusinessPerfusionRheumatismAnnals of the Rheumatic Diseases
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondylo…

2022

AbstractAn accurate prediction of cardiovascular (CV) risk in patients with Axial Spondyloarthritis (axSpA) is a strong unmet need, as CV risk algorithms poorly perform in these subjects. The aim of this study was to establish whether the persistence of high C-reactive protein (CRP) and high disease activity may be considered predictive factors of CVD in axSpA. 295 patients without personal history of CVD, were consecutively enrolled in this study. To evaluate the relationship between CV events occurrence (fatal and non-fatal) and the persistence of increased CRP levels, ASDAS (Ankylosing Spondylitis Disease Activity Score) > 2.1, and BASDAI (Bath Ankylosing Spondylitis Disease Activity)…

Axial SpondyloarthritiMultidisciplinaryPersistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritisSpondylarthritiSettore MED/16Severity of Illness IndexC-Reactive ProteinRetrospective StudieCardiovascular DiseasesCardiovascular DiseaseSpondylarthritisHumansSpondylitis AnkylosingAxial SpondyloarthritisHumanRetrospective Studies
researchProduct

Cardiovascular disease in primary sjögren’s syndrome

2018

Background A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren's syndrome (pSS) experienced an increased risk of CVD. Objective This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion Disease-related characteristics and traditional CV risk factors contribute to observed athero…

medicine.medical_specialtyFuture studiesEndothelial damageDiseaseType 2 diabetesComorbidity030204 cardiovascular system & hematologySjögren syndrome03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumans030212 general & internal medicinePharmacologybusiness.industryRisk FactorGeneral Medicinemedicine.diseaseAtherosclerosisCardiovascular diseaseCardiovascular riskComorbiditySjögren syndromestomatognathic diseasesSettore MED/16 - ReumatologiaAtherosclerosis; Cardiovascular disease; Cardiovascular risk; Comorbidity; Endothelial damage; Sjögren syndrome; PharmacologyIncreased riskSjogren's SyndromeClose relationshipCardiovascular DiseasesAtherosclerosiSjogren sbusinessHuman
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

Interleukin (IL)-9/IL-9R axis drives γδ T cells activation in psoriatic arthritis patients

2016

Summary Cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-12, interferon (IFN)-γ, IL-23 and, more recently, IL-9, have been implicated in the initiation/maintenance of inflammation in psoriasis and psoriatic arthritis (PsA). In the present study we aimed to characterize the role of γδ T cells in peripheral blood and synovial fluid of PsA patients and to investigate their response to in-vitro stimulation with antigen or cytokines (IL-9 and IL-23). γδ T cells isolated from peripheral blood mononuclear cells and synovial fluid were analysed by flow cytometry to evaluate the phenotype and cytokine production. IL-23R and IL-9R gene expression were also evaluated by reverse trans…

AdultMale0301 basic medicinepsoriatic arthritimedicine.medical_treatmentImmunologyInflammationLymphocyte ActivationSeverity of Illness IndexPeripheral blood mononuclear cellImmunophenotypingγδ-T cellsYoung Adult03 medical and health sciences0302 clinical medicineAntigenT-Lymphocyte SubsetsInterferonSynovial FluidmedicineHumansImmunology and AllergySynovial fluidAgedReceptors Interleukin-9psoriatic arthritis030203 arthritis & rheumatologybusiness.industryArthritis PsoriaticInterleukin-9InterleukinReceptors Antigen T-Cell gamma-deltaOriginal ArticlesIL-9; IL-9R; psoriatic arthritis; γδ-T cells; Immunology and Allergy; ImmunologyMiddle AgedIL-9IL-9RSettore MED/16 - ReumatologiaPhenotype030104 developmental biologyCytokineImmunologyFemaleTumor necrosis factor alphamedicine.symptombusinessBiomarkersmedicine.drugClinical and Experimental Immunology
researchProduct

Is minor salivary gland biopsy more than a diagnostic tool in primary Sjorgren's syndrome? Association between clinical, histopathological, and molec…

2014

Objectives: Several histological scoring systems, including the focus score, performed in minor salivary glands (MSGs) by hematoxylin-eosin (H&E) staining, have been employed in clinical practice to assess the inflammatory infiltrate and provide the diagnosis of primary Sjorgren's syndrome (pSS). Aims of this study were to integrate different scoring systems and identify potential differences in the molecular profile of lymphoid cytokines related to germinal center (GC) formation and clinical subsets in pSS. Methods: Overall, 104 pSS patients and 40 subjects with sicca non-pSS were retrospectively evaluated. MSG biopsies were evaluated by H&E and immunofluorescence to assess histological pa…

MalePathologyT-LymphocytesBiopsyRetrospective Studiesalivary glands biopsyB-Lymphocytesmedicine.diagnostic_testbiologyLTαLTβMedicine (all)HypergammaglobulinemiaB-LymphocyteCXCL13CXCL12Middle AgedSjogren's syndrome salivary glands biopsySjogren's SyndromeCytokinesBAFFFemaleAntibodyHumanmusculoskeletal diseasesAdultmedicine.medical_specialtyBAFF; CCL19; CCL21; CCR7; CXCL12; CXCL13; CXCR4; CXCR5; Germinal center; LTα; LTβ; Minor salivary glands; Sjorgren's syndrome; Adult; B-Lymphocytes; Biomarkers; Biopsy; Cytokines; Female; Germinal Center; Humans; Male; Middle Aged; Retrospective Studies; Salivary Glands Minor; Sjogren's Syndrome; T-Lymphocytes; Rheumatology; Anesthesiology and Pain Medicine; Medicine (all)ImmunofluorescenceSalivary Glands MinorSalivary Glandstomatognathic systemRheumatologyInternal medicineBiopsyCCL19medicineHumansCXCL13B-cell activating factorCytokineRetrospective StudiesCXCR4Minor salivary glandbusiness.industryRetrospective cohort studyGerminal centerBiomarkermedicine.diseaseeye diseasesRheumatologyCXCR5Minorstomatognathic diseasesAnesthesiology and Pain MedicineT-LymphocyteSjorgren's syndromebiology.proteinbusinessBiomarkersCCL21CCR7
researchProduct

AB0919 H-Ferritin and CD68+/H-ferritin+ Cells Are Increased in The Skin of Adult Onset Still's Disease Patients and Correlate with The Disease Activi…

2016

Background Adult onset Still9s disease (AOSD) is an inflammatory disease, characterized by high spiking fevers, arthritis, salmon-pink erythema and multivisceral involvement [1]. During AOSD, exceptionally high serum levels of ferritin may be observed and they might contribute to production of proinflammatory molecules [2]. Ferritin is composed by 24 subunits, heavy (H) subunits and light (L) subunits. The ferritin enriched in L subunits (L-ferritin) and the ferritin enriched in H subunits (H-ferritin) may be recognized in different tissues [3]. Objectives To investigate the skin tissue expression of both H-and L-ferritin and the number of macrophages expressing these molecules, in the infl…

0301 basic medicineErythemabiologyCD68Septic shockbusiness.industryImmunologyArthritismedicine.disease_causemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityProinflammatory cytokineFerritin03 medical and health sciences030104 developmental biologyRheumatologyMacrophage activation syndromeImmunologymedicinebiology.proteinImmunology and Allergymedicine.symptombusinessAnnals of the Rheumatic Diseases
researchProduct

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

2013

Introduction Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. …

AdultMaleReceptors CXCR5musculoskeletal diseasesReceptors CXCR4Salivamedicine.medical_specialtySjogren's syndrome RituximabTime FactorsBiopsyImmunologyGene ExpressionDiseaseSalivary GlandsAntibodies Monoclonal Murine-Derivedstomatognathic systemRheumatologyInternal medicineBiopsyHumansImmunology and AllergyMedicineProspective StudiesProspective cohort studyAdverse effectFatiguePain Measurementmedicine.diagnostic_testSalivary glandReverse Transcriptase Polymerase Chain Reactionbusiness.industryMiddle AgedChemokine CXCL13Chemokine CXCL12Rheumatologystomatognathic diseasesTreatment Outcomemedicine.anatomical_structureSjogren's syndromeAntirheumatic AgentsImmunologyFemaleRituximabSelf ReportRituximabbusinessFollow-Up StudiesResearch Articlemedicine.drug
researchProduct

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

2022

© 2022 Elsevier Inc.Background/objectives: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. Methods: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Mei…

RegistrieAdultMaleSettore MED/16 - REUMATOLOGIAInterleukin-6Innovative biotechnologiesTocilizumabAdult-onset Still's diseaseAntibodies Monoclonal HumanizedPersonalized medicineAdult-onset Still's disease; Innovative biotechnologies; Interleukin-6; Personalized medicine; TocilizumabSettore MED/38 - Pediatria Generale E SpecialisticaAnesthesiology and Pain MedicineRheumatologyInnovative biotechnologieStill's diseaseHumansFemaleRegistriesImmunotherapyTocilizumab.Still's Disease Adult-OnsetHuman
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular…

2015

Summary In this work, we aimed to evaluate the levels of ferritin enriched in H subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the cells expressing these two molecules in the lymph node (LN) biopsies obtained from adult-onset Still's disease (AOSD) patients, and the possible correlation among these data and the severity of the disease. Ten patients with AOSD underwent LN biopsy. All the samples were stained by immunofluorescence. A statistical analysis was performed to estimate the possible correlation among both H-ferritin and L-ferritin tissue expression and the clinical picture of the disease. Furthermore, the same analysis was performed to evaluate the possib…

0301 basic medicineAdult-OnsetMalePathologyMacrophageApoferritinAdult-onset Still's disease; H-ferritin; Hyperferritinaemic syndrome; Macrophage; Adult; Aged; Antigens CD; Antigens Differentiation Myelomonocytic; Apoferritins; Biopsy; Female; Ferritins; Fluorescent Antibody Technique; Humans; Lymph Nodes; Macrophages; Male; Middle Aged; Still's Disease Adult-Onset; Immunology; Immunology and AllergyH-ferritinBiopsyFluorescent Antibody TechniquePathogenesis0302 clinical medicineMacrophageImmunology and AllergyLymph nodemedicine.diagnostic_testCD68Lymph NodeMiddle AgedCDmedicine.anatomical_structureAntigenDifferentiationFemaleLymphHyperferritinaemic syndromeStill's Disease Adult-OnsetHumanAdultmedicine.medical_specialtyImmunologyAntigens Differentiation MyelomonocyticBiologyImmunofluorescenceAdult-onset Still's disease03 medical and health sciencesAntigens CDBiopsymedicineHumansAntigensAged030203 arthritis & rheumatologyFerritinMacrophagesOriginal ArticlesMyelomonocyticStill's DiseaseFerritinSettore MED/16 - Reumatologia030104 developmental biologyImmunologyApoferritinsFerritinsbiology.proteinLymph Nodes
researchProduct

Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study

2021

The objective of this study is to describe the possible prognostic impact of smoking habit on adult-onset Still’s disease (AOSD) patients, by the assessment of clinical characteristics, life-threatening complications occurrence, and mortality in smokers than non-smokers. A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was conducted. Out of 185 AOSD assessed patients, 45 smokers were identified. These showed a higher frequency of pericarditis (35.5% vs 16.4%, p = 0.011), pleuritis (33.3% vs 14.3%, p = 0.008), and abdominal pain (17.7% vs 6.4%, p = 0.035). Furthermore, sm…

Adultmedicine.medical_specialtyAbdominal painAdult-onset; Macrophage activation syndrome; Mortality; Smoking; Still’s diseasePericarditisRheumatologyInternal medicineRisk of mortalityHumansMedicineMortalityRetrospective Studiesbusiness.industryStill’s diseaseSmokingRetrospective cohort studyGeneral MedicinePrognosismedicine.diseaseAdult-onsetRheumatologyMacrophage activation syndromeMacrophage activation syndromeCohortmedicine.symptombusinessStill's Disease Adult-OnsetSerositis
researchProduct

IL-9 IN PsA

2016

Objective. To investigate the expression and tis- sue distribution of Th9-related cytokines in patients with psoriatic arthritis (PsA). Methods. Quantitative gene expression analysis of Th1, Th17, and Th9 cytokines was performed in intestinal biopsy samples obtained from patients with PsA, HLA2B272positive patients with ankylosing spondylitis (AS), patients with Crohn’s disease (CD), and healthy controls. Expression and tissue distribu- tion of interleukin-23 (IL-23), IL-17, IL-22, IL-9, and IL-9 receptor (IL-9R) were evaluated by immunohisto- chemistry and confocal microscopy. Flow cytometry was used to study the frequency of Th9 cells among periph- eral blood, lamina propria, and synovial…

InflammationMalePsoriatic arthritis gut inflammation synoviasynoviaArthritis PsoriaticSynovial MembranePsoriatic ArthritisInterleukin-9T-Lymphocytes Helper-InducerReceptors Tumor Necrosis FactorIntestinesSettore MED/16 - ReumatologiaGene Expression RegulationTh9 cellHumansFemaleUstekinumabGutSynovial Tissuegut inflammationInterleukin-9 Th9 cells Gut Synovial Tissue Psoriatic Arthritis
researchProduct

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibrobla…

2018

Abstract Background Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively. There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process. Methods After ethical approval was obtained, skin biopsies were co…

0301 basic medicineMalelcsh:Diseases of the musculoskeletal systemProton Pump InhibitorFibrosiCellular differentiationmedicine.medical_treatmentSystemic sclerosiFibrosisImmunology and AllergyMedicineMyofibroblastsskin and connective tissue diseasesCells CulturedSkinintegumentary systemCell DifferentiationMiddle AgedMesenchymal Stem CellBenzamidesSystemic sclerosisFemaleMyofibroblastResearch ArticleHumanAdultStromal cellImmunology03 medical and health sciencesYoung AdultRheumatologyBenzamideAntigens CDAntigens NeoplasmHumansGene silencingCell ProliferationMyofibroblastScleroderma Systemicbusiness.industryGrowth factorMesenchymal stem cellStromal CellMesenchymal Stem CellsProton Pump Inhibitorsmedicine.diseaseFibrosisCD248Settore MED/16 - Reumatologia030104 developmental biologyCancer researchStromal Cellslcsh:RC925-935CD248; Fibrosis; Systemic sclerosis; Rheumatology; Immunology and Allergy; ImmunologybusinessTransforming growth factor
researchProduct

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

Additional file 1: of Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observatio…

2019

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology* (DOC 96 kb)

researchProduct

Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry

2023

AbstractThis study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (…

Settore MED/16 - REUMATOLOGIABehçet's diseaseBehçet’s syndromeArthritisArthritis; Behçet’s syndrome; International registry; Pediatric rheumatology; Rare diseasesRare diseasesSettore MED/38 - Pediatria Generale E SpecialisticaArthritis Behçet’s syndrome International registry Pediatric rheumatology Rare diseasesInternational registryEmergency MedicineInternal MedicineAutoinflammationPediatric rheumatologyArthriti
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

Additional file 2 of Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis

2021

Additional file 2: Supplementary material 2. Arthritis score evaluation. The histogram showed the median and the range of the arthritis score evaluated the day 35. The collagen induced a significant increase of arthritis score when compared to control group, and 30 mg/Kg/day of tofacitinib prevented the increase of arthritis score (**=p=0.001; ***= p

researchProduct

Additional file 1 of Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis

2021

Additional file 1: Supplementary material 1. Mice treatments. The first day (day 0) of the procedure, 64 DBA/1 J mice were divided in 2 groups. One control group (n=32) receiving saline solution and one CIA group (n=32) receiving 100 μg of bovine type II collagen, emulsified with an equal volume of Freund’s complete adjuvant. After 18 days, the control group received saline solution and CIA mice received type II collagen and Freund’s incomplete adjuvant. At the day 19, controls and CIA mice were divided into 2 subgroups: one receiving vehicle (n=16) and one receiving 30 mg/kg/day of tofacitinib (n=16). After 35 days the first collagen administration, the mice were sacrificed and the blood c…

researchProduct